BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Prognosis
124 results:

  • 1. Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and foxp3 in colorectal cancer draining lymph nodes.
    Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
    Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
    Frei AL; McGuigan A; Sinha RRAK; Jabbar F; Gneo L; Tomasevic T; Harkin A; Iveson T; Saunders MP; Oien KA; Maka N; Pezzella F; Campo L; Browne M; Glaire M; Kildal W; Danielsen HE; Hay J; Edwards J; Sansom O; Kelly C; Tomlinson I; Kerr R; Kerr D; Domingo E; ; Church DN; Koelzer VH
    Lancet Oncol; 2024 Feb; 25(2):198-211. PubMed ID: 38301689
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy.
    Edin S; Gylling B; Li X; Stenberg Å; Löfgren-Burström A; Zingmark C; van Guelpen B; Ljuslinder I; Ling A; Palmqvist R
    Br J Cancer; 2024 Jan; 130(1):143-150. PubMed ID: 38040818
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Propolis Has an Anticancer Effect on Early Stage colorectal cancer by Affecting Epithelial Differentiation and Gut Immunity in the Tumor Microenvironment.
    Shen MH; Liu CY; Chang KW; Lai CL; Chang SC; Huang CJ
    Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960147
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in cancer.
    Pinioti S; Sharma H; Flerin NC; Yu Q; Tzoumpa A; Trusso Cafarello S; De Bousser E; Callewaert N; Oldenhove G; Schlenner S; Thienpont B; Garg AD; Di Matteo M; Mazzone M
    Cancer Immunol Res; 2023 Dec; 11(12):1611-1629. PubMed ID: 37933083
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Immune microenvironment and lymph node yield in colorectal cancer.
    Lee SH; Pankaj A; Neyaz A; Ono Y; Rickelt S; Ferrone C; Ting D; Patil DT; Yilmaz O; Berger D; Deshpande V; Yılmaz O
    Br J Cancer; 2023 Oct; 129(6):917-924. PubMed ID: 37507544
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Relationship Between Infiltration of CD163+ TAMs, foxp3+ Tregs, or CD66b+ TANs and Cell Differentiation in colorectal cancer Tissues.
    Wang X; Bai Y; Zhou Z; Ye B; Chen Z; Chen X; Wu W
    Turk J Gastroenterol; 2023 Jul; 34(7):747-752. PubMed ID: 37232465
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. IL-6 Levels Correlate with prognosis and Immunosuppressive Stromal Cells in Patients with colorectal cancer.
    Yamamoto T; Tsunedomi R; Nakajima M; Suzuki N; Yoshida S; Tomochika S; Xu M; Nakagami Y; Matsui H; Tokumitsu Y; Shindo Y; Watanabe Y; Iida M; Takeda S; Hazama S; Tanabe T; Ioka T; Hoshii Y; Kiyota A; Takizawa H; Kawakami Y; Ueno T; Nagano H
    Ann Surg Oncol; 2023 Aug; 30(8):5267-5277. PubMed ID: 37222942
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Immunological and Clinico-Molecular Features of Tumor Border Configuration in colorectal cancer.
    Sonal S; Deshpande V; Ting DT; Neyaz A; Pankaj A; Taylor MS; Dinaux AM; Leijssen LG; Boudreau C; Berger DL
    J Am Coll Surg; 2023 Jan; 236(1):126-134. PubMed ID: 36519916
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Bile acid distributions, sex-specificity, and prognosis in colorectal cancer.
    Cai Y; Shen X; Lu L; Yan H; Huang H; Gaule P; Muca E; Theriot CM; Rattray Z; Rattray NJW; Lu J; Ahuja N; Zhang Y; Paty PB; Khan SA; Johnson CH
    Biol Sex Differ; 2022 Oct; 13(1):61. PubMed ID: 36274154
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. CD4 and foxp3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule.
    Nakagami Y; Hazama S; Suzuki N; Yoshida S; Tomochika S; Matsui H; Shindo Y; Tokumitsu Y; Matsukuma S; Watanabe Y; Iida M; Tsunedomi R; Takeda S; Fujita T; Kawakami Y; Ogihara H; Hamamoto Y; Ioka T; Tanabe T; Ueno T; Nagano H
    BMC Cancer; 2022 Oct; 22(1):1071. PubMed ID: 36253752
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Immune Evasion and Drug Resistance Mediated by USP22 in cancer: Novel Targets and Mechanisms.
    Guo J; Zhao J; Fu W; Xu Q; Huang D
    Front Immunol; 2022; 13():918314. PubMed ID: 35935969
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Molecular Basis of Extramural Vascular Invasion (EMVI) in colorectal Carcinoma.
    Sonal S; Deshpande V; Ting DT; Cusack JC; Parikh AR; Neyaz A; Pankaj A; Taylor MS; Dinaux AM; Leijssen LGJ; Boudreau C; Locascio JJ; Kunitake H; Goldstone RN; Bordeianou LG; Cauley CE; Ricciardi R; Berger DL
    Ann Surg Oncol; 2022 Nov; 29(12):7372-7382. PubMed ID: 35917013
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. C-reactive protein/albumin ratio and Glasgow prognostic score are associated with prognosis and infiltration of foxp3+ or CD3+ lymphocytes in colorectal liver metastasis.
    Kanno H; Hisaka T; Akiba J; Hashimoto K; Fujita F; Akagi Y
    BMC Cancer; 2022 Aug; 22(1):839. PubMed ID: 35915403
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical, pathological genetics and intratumoral immune milieu of serrated adenocarcinoma of the colon.
    Yılmaz O; Crabbe A; Neyaz A; Pankaj A; Lee SH; Hosseini S; Rickelt S; Cerda S; Zhao Q; Leijsen L; Dineaux A; Shroff SG; Crotty R; Zhang ML; Yilmaz OH; Patil DT; Berger D; Deshpande V
    Histopathology; 2022 Sep; 81(3):380-388. PubMed ID: 35789111
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.
    Yılmaz O; Pankaj A; Neyez A; Rickelt S; Taylor M; Lang ER; Leijsen L; Dinaux A; Shroff SG; Crotty R; Zhang ML; Cerda S; Zhao Q; Ferrone C; Ting DT; Patil DT; Yilmaz O; Berger D; Deshpande V
    Mod Pathol; 2022 Nov; 35(11):1740-1748. PubMed ID: 35773332
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immune response in colorectal carcinoma: a review of its significance as a predictive and prognostic biomarker.
    Bell PD; Pai RK
    Histopathology; 2022 Dec; 81(6):696-714. PubMed ID: 35758208
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer.
    Bergsland CH; Jeanmougin M; Moosavi SH; Svindland A; Bruun J; Nesbakken A; Sveen A; Lothe RA
    Mod Pathol; 2022 Sep; 35(9):1236-1246. PubMed ID: 35484226
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.